Inmagene Doses First Patient in Phase 2a Trial of IMG-007, an Anti-OX40 Monoclonal Antibody with an Extended Half-life, for the Treatment of Alopecia Areata
- Written by PR Newswire
- IMG-007 is a novel anti-OX40 monoclonal antibody (mAb) engineered for potentially once every 12 weeks dosing and an improved safety profile
- IMG-007 is being evaluated for the treatment of alopecia areata (AA) and atopic dermatitis (AD)
- An interim data readout in AA is expected in Q3 2024
SAN DIEGO, Oct. 13, 2023 /PRNewswire/ -- Inmagene...
